Theromics Taps Industry Vet to Commercialize New Cancer Ablation Tech

WEST BRIDGEWATER, Mass. – May 21, 2026 – Biotechnology firm Theromics Inc. has appointed Andrew C. Zeringue, a seasoned executive in interventional oncology, as its new Chief Executive Officer. The move signals a strategic pivot for the company from research and development toward the critical phase of commercialization for its innovative cancer-fighting technologies.

Theromics is focused on advancing ablation therapeutics, a field centered on using energy—like heat or cold—to destroy tumors in a minimally invasive way. Zeringue’s appointment brings nearly two decades of experience in scaling such technologies from regulatory approval to widespread market adoption, a skillset Theromics is betting on to bring its flagship products to clinicians and patients.

"We reviewed many candidates for this position and Andrew's extensive experience in interventional oncology and thermal ablation quickly distinguished him as the right choice to steer Theromics into its next chapter," said Joseph Amaral, M.D., Chairman of the Board of Theromics. "Under Andrew's leadership we are confident the company is well positioned to advance its platform technologies toward commercialization and deliver innovative solutions that help physicians address cancer treatment challenges, including reducing the risk of local cancer recurrence."

A Proven Commercial Leader Takes the Helm

Andrew Zeringue’s career is a roadmap of successful medical technology commercialization, particularly within the specialized niche of interventional oncology. His track record includes key leadership roles at companies that have defined the modern ablation landscape. Most recently, he was instrumental in leading the U.S. strategy for Quantum Surgical's Epione® Interventional Oncology Robot, a sophisticated system that enhances physician precision during tumor ablation procedures. His tenure there culminated in a milestone acquisition where Quantum Surgical purchased NeuWave Medical from Johnson & Johnson, creating a new entity, Precision IO Group, that combines robotics with a leading microwave ablation platform.

Prior to that, Zeringue held senior positions at NeuWave Medical when it was a subsidiary of Johnson & Johnson. NeuWave was a market leader in microwave ablation, with its systems used in an estimated 70% of top U.S. cancer centers. His experience also extends to leadership roles at BTG, where he was involved in commercializing interventional oncology products before its acquisition by Boston Scientific, and at AngioDynamics, a company with a deep portfolio in oncology devices, including the pioneering NanoKnife system.

This extensive background provides Zeringue with a unique perspective on the entire product lifecycle, from development to scalable adoption. His work has consistently involved collaborating with physicians and academic medical centers to integrate first-in-category platforms into clinical practice. This experience is precisely what a company like Theromics needs as it prepares to navigate the complex pathway of FDA clearance and market entry.

Targeting a Critical Unmet Need: Local Cancer Recurrence

At the heart of Theromics' mission is a persistent and challenging problem in oncology: the local recurrence of cancer after minimally invasive treatment. While thermal ablation procedures are highly effective, a significant clinical challenge remains in ensuring that the entire tumor is destroyed, preventing cancer cells from surviving at the margins and causing a relapse. Inconsistent energy delivery within the diverse and complex environment of soft tissue can lead to incomplete treatment zones.

Theromics aims to solve this problem with its proprietary HeatSYNC™ gel platform. Rather than developing a new energy source, the company has created a biomaterial designed to be used alongside existing thermal ablation devices. The gel is intended to enhance and standardize thermal energy transfer within the tissue, helping to create more predictable and complete ablation zones. The goal is to give physicians greater confidence that they have eradicated the entire target, thereby reducing the risk of local recurrence.

"I believe Theromics is uniquely positioned to help advance the next generation of local tumor therapy," said Zeringue. "Local recurrence following minimally invasive cancer treatment remains a significant clinical challenge, and Theromics is developing technologies designed to support more effective and predictable therapy delivery." He noted the company's founding by internationally recognized thought leaders in the field as a key strength in its mission.

The company is currently advancing the HeatSYNC™ platform toward FDA clearance. Beyond thermal ablation, Theromics is also developing a broader suite of solutions, including its CryoSYNC™ platform for cold-based ablation and the TACT™ (Thermally Activated Combination Therapy) platform, which aims to combine localized drug delivery with thermal energy to further improve outcomes.

Navigating a Dynamic and Competitive Market

Zeringue takes the helm as Theromics prepares to enter a robust and rapidly expanding market. The global ablation devices market was valued at approximately $8.05 billion in 2025 and is projected to surge to over $14.4 billion by 2031, growing at a compound annual growth rate of over 10%. This growth is fueled by an aging population, a rising incidence of cancer, and a strong clinical preference for minimally invasive procedures that reduce recovery times and complications.

The oncology segment represents a major portion of this market, with interventional oncology therapies leading the charge. Theromics will be competing in a space populated by established giants like Medtronic, Boston Scientific, and Johnson & Johnson, as well as innovative players focused on specific modalities like radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation.

However, Theromics' strategy appears to be one of collaboration rather than direct competition with these energy-based systems. By developing an enhancement technology, the HeatSYNC™ platform is positioned as an adjunct that can improve the performance of many existing devices, offering a unique value proposition. This approach differentiates it from companies focused on robotics for improved navigation or advanced software for better imaging. Theromics is tackling the fundamental physics of the procedure itself.

With Zeringue's deep network and experience launching novel technologies into this very ecosystem, the company is strategically poised. His leadership will be crucial in demonstrating the clinical and economic value of the HeatSYNC™ platform to hospitals and physicians, carving out a new niche in the bustling interventional oncology landscape and potentially setting a new standard for ablation outcomes.